Erasca Reports Second Quarter 2024 Business Updates and Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/24/2026
- Wall St futures rise after tech rout; Mideast, tariffs in focus
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil retreats from above $100, but set for weekly rise on Middle East escalation
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- Americold to wind down Ahold Delhaize facilities, take $305M charge
- Wall St falls as tech earnings spark AI spending worries and oil hits $100
- Did Google and Tesla just break AI trade’s bull case?
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
- Matador Resources to acquire Paloma Permian for $1.275B
Erasca Inc (ERAS) PT Lowered to $3 at Goldman Sachs
August 13, 2024 1:52 PM EDTGoldman Sachs analyst Chris Shibutani lowered the price target on Erasca Inc (NASDAQ: ERAS) to $3.00 (from $4.00) while maintaining a Buy rating.
The analyst comments "Post the company's prior announcement in May of a strategic reset with subsequent financings, the company's 2Q24 operational and program updates (see... More
Erasca Inc (ERAS) PT Raised to $6 at H.C. Wainwright
August 13, 2024 6:11 AM EDTH.C. Wainwright analyst Andres Y. Maldonado raised the price target on Erasca Inc (NASDAQ: ERAS) to $6.00 (from $5.00) while maintaining a Buy rating.
The analyst comments "What to expect from the newly initiated SEACRAFT-2 study. Erasca recently announced the initiation of the global SEACRAFT-2 Phase 3 trial to evaluate the pan-RAF inhibitor naporafenib in combination with the MEK inhibitor trametinib for patients with NRAS-mutant melanoma. Our positive outlook on this program is... More
